At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
MLYS Mineralys Therapeutics, Inc.
Post-Market Trading 11-25 18:14:52 EST
12.70
+0.21
+1.68%
盘后12.70
+0.000.00%
16:02 EST
High13.33Low12.70Vol210.14K
Open12.70D1 Closing12.49Amplitude5.04%
Mkt Cap632.06MTradable Cap343.64MTotal Shares49.77M
T/O2.71MT/O Rate0.78%Tradable Shares27.06M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--
Q3 2024 Mineralys Therapeutics Inc Earnings Call
Thomson Reuters StreetEvents  ·  11-12
Q3 2024 Mineralys Therapeutics Inc Earnings Call
Mineralys Therapeutics, Inc. (MLYS) Gets a Buy from Stifel Nicolaus
TIPRANKS  ·  11-12
Mineralys Therapeutics, Inc. (MLYS) Gets a Buy from Stifel Nicolaus
Mineralys Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary
Reuters  ·  11-12
Mineralys Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary
Mineralys Therapeutics Q3 Net Loss Widens
MT Newswires Live  ·  11-12
Mineralys Therapeutics Q3 Net Loss Widens
Mineralys Therapeutics Q3 2024 GAAP EPS $(1.13) Misses $(0.83) Estimate
Benzinga  ·  11-12
Mineralys Therapeutics Q3 2024 GAAP EPS $(1.13) Misses $(0.83) Estimate
Mineralys Therapeutics Q3 Operating Expenses USD 60.106 Million
THOMSON REUTERS  ·  11-12
Mineralys Therapeutics Q3 Operating Expenses USD 60.106 Million
Calendar of U.S. Earnings Expected in the Week Ahead
Dow Jones  ·  11-11
Calendar of U.S. Earnings Expected in the Week Ahead
Mineralys Therapeutics Inc expected to post a loss of 83 cents a share - Earnings Preview
Reuters  ·  11-09
Mineralys Therapeutics Inc expected to post a loss of 83 cents a share - Earnings Preview
Mineralys Therapeutics to Participate in Upcoming Investor Conferences
GlobeNewswire  ·  11-06
Mineralys Therapeutics to Participate in Upcoming Investor Conferences
Calendar of U.S. Earnings Expected in the Week Ahead
Dow Jones  ·  11-05
Calendar of U.S. Earnings Expected in the Week Ahead
Mineralys Therapeutics to Announce Third Quarter 2024 Financial Results and Host Conference Call on Monday, November 11, 2024
GlobeNewswire  ·  11-05
Mineralys Therapeutics to Announce Third Quarter 2024 Financial Results and Host Conference Call on Monday, November 11, 2024
BRIEF-Mineralys Therapeutics Completes Enrollment Ahead Of Schedule In Launch-HTN, The Second Pivotal Trial Of Lorundrostat For The Treatment Of Hypertension
Reuters  ·  10-30
BRIEF-Mineralys Therapeutics Completes Enrollment Ahead Of Schedule In Launch-HTN, The Second Pivotal Trial Of Lorundrostat For The Treatment Of Hypertension
Mineralys Therapeutics Completes Enrollment Ahead of Schedule in Launch-Htn, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension
THOMSON REUTERS  ·  10-30
Mineralys Therapeutics Completes Enrollment Ahead of Schedule in Launch-Htn, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension
Mineralys Therapeutics Inc - Topline Data From Launch-Htn Trial Expected Mid First Half of 2025
THOMSON REUTERS  ·  10-30
Mineralys Therapeutics Inc - Topline Data From Launch-Htn Trial Expected Mid First Half of 2025
Mineralys Therapeutics to host KOL event on uncontrolled, resistant hypertension
TIPRANKS  ·  10-22
Mineralys Therapeutics to host KOL event on uncontrolled, resistant hypertension
Here's Why We're Not Too Worried About Mineralys Therapeutics' (NASDAQ:MLYS) Cash Burn Situation
Simply Wall St.  ·  10-07
Here's Why We're Not Too Worried About Mineralys Therapeutics' (NASDAQ:MLYS) Cash Burn Situation
BRIEF-Mineralys Therapeutics Completes Target Enrollment In Pivotal Advance-HTN Trial Of Lorundrostat For The Treatment Of Hypertension
Reuters  ·  09-25
BRIEF-Mineralys Therapeutics Completes Target Enrollment In Pivotal Advance-HTN Trial Of Lorundrostat For The Treatment Of Hypertension
Mineralys Therapeutics Completes Target Enrollment in Pivotal Advance-Htn Trial of Lorundrostat for the Treatment of Hypertension
THOMSON REUTERS  ·  09-25
Mineralys Therapeutics Completes Target Enrollment in Pivotal Advance-Htn Trial of Lorundrostat for the Treatment of Hypertension
Mineralys Therapeutics Inc - Expects to Announce Topline Data in Q1 2025
THOMSON REUTERS  ·  09-25
Mineralys Therapeutics Inc - Expects to Announce Topline Data in Q1 2025
Mineralys In Hypertension: Upcoming Catalysts And Strong Positioning
seekingalpha  ·  09-18
Mineralys In Hypertension: Upcoming Catalysts And Strong Positioning

Introduction

Company Name.
Mineralys Therapeutics, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Issue price:
--